Patents by Inventor Simon Geissler

Simon Geissler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210085611
    Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-tnorpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 25, 2021
    Applicant: Merck Patent GmbH
    Inventors: Simon GEISSLER, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
  • Publication number: 20200237733
    Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Simon GEISSLER, Stefan SCHILLER, Meike HARMS, Holger KUBAS, Markus WEIGANDT, Michael LANGE
  • Publication number: 20200197341
    Abstract: The present invention relates to a compound for use in a method for treating a musculoskeletal injury, wherein the compound is a regulator of the pro-inflammatory response and particularly being capable of upregulating regulatory T cells and/or M2-macrophages; and/or being capable of downregulating the biological activity of effector CD8+ cells, and further comprising the dosage regimen administering an initial dose of said compound to a patient not before 24 hours after said musculoskeletal injury.
    Type: Application
    Filed: August 31, 2018
    Publication date: June 25, 2020
    Applicant: CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
    Inventors: Katharina SCHMIDT-BLEEK, Hans-Dieter VOLK, Sebastian WENDLER, Georg N. DUDA, Simon REINKE, Sven GEISSLER, Taimoor Hasan QAZI, Anke DIENELT, Hanna SCHELL
  • Publication number: 20200182872
    Abstract: The present invention relates to a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28? and CD8+CD57+CD28? in a sample obtained from a patient. The invention further relates to a system for predicting the probability of having or developing a non-fusion.
    Type: Application
    Filed: May 29, 2018
    Publication date: June 11, 2020
    Applicant: CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
    Inventors: Simon REINKE, Sven GEISSLER, Georg DUDA, Hans-Dieter VOLK, Michael FUCHS, Katharina SCHMIDT-BLEEK, Patrick STRUBE, Matthias PUMBERGER
  • Publication number: 20200116721
    Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Applicant: Charite Universitätsmedizin Berlin
    Inventors: Georg DUDA, Hans-Dieter VOLK, Simon REINKE, Christian MEISEL, Christian KLEBER, Sven GEISSLER, Katharina SCHMIDT-BLEEK
  • Publication number: 20160279213
    Abstract: The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules.
    Type: Application
    Filed: December 16, 2014
    Publication date: September 29, 2016
    Inventors: Simon Geissler, Patrizia Boniforte, Joerg Plaschke, Markus Weigandt, Stefan Jaekel, Roland Kellner, Thomas Rysiok, Dirk Mueller-Pompalla, Kenneth Hance
  • Patent number: 8211948
    Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: July 3, 2012
    Assignee: Merck Patent GmbH
    Inventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth
  • Publication number: 20110015266
    Abstract: The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion.
    Type: Application
    Filed: February 26, 2009
    Publication date: January 20, 2011
    Inventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth